These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 34931199)

  • 1. Plasma neutralization properties of the SARS-CoV-2 Omicron variant.
    Schmidt F; Muecksch F; Weisblum Y; Da Silva J; Bednarski E; Cho A; Wang Z; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    medRxiv; 2021 Dec; ():. PubMed ID: 34931199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.
    Garcia-Beltran WF; St Denis KJ; Hoelzemer A; Lam EC; Nitido AD; Sheehan ML; Berrios C; Ofoman O; Chang CC; Hauser BM; Feldman J; Roederer AL; Gregory DJ; Poznansky MC; Schmidt AG; Iafrate AJ; Naranbhai V; Balazs AB
    Cell; 2022 Feb; 185(3):457-466.e4. PubMed ID: 34995482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant.
    Edara VV; Manning KE; Ellis M; Lai L; Moore KM; Foster SL; Floyd K; Davis-Gardner ME; Mantus G; Nyhoff LE; Bechnak S; Alaaeddine G; Naji A; Samaha H; Lee M; Bristow L; Hussaini L; Ciric CR; Nguyen PV; Gagne M; Roberts-Torres J; Henry AR; Godbole S; Grakoui A; Sexton M; Piantadosi A; Waggoner JJ; Douek DC; Anderson EJ; Rouphael N; Wrammert J; Suthar MS
    bioRxiv; 2021 Dec; ():. PubMed ID: 34981056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.
    Garcia-Beltran WF; St Denis KJ; Hoelzemer A; Lam EC; Nitido AD; Sheehan ML; Berrios C; Ofoman O; Chang CC; Hauser BM; Feldman J; Gregory DJ; Poznansky MC; Schmidt AG; Iafrate AJ; Naranbhai V; Balazs AB
    medRxiv; 2021 Dec; ():. PubMed ID: 34931201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals.
    Lapa D; Grousova DM; Matusali G; Meschi S; Colavita F; Bettini A; Gramigna G; Francalancia M; Garbuglia AR; Girardi E; Puro V; Antinori A; Kovyrshina AV; Dolzhikova IV; Shcheblyakov DV; Tukhvatulin AI; Zubkova OV; Gushchin VA; Logunov DY; Naroditsky BS; Vaia F; Gintsburg AL
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose.
    Muecksch F; Wang Z; Cho A; Gaebler C; Tanfous TB; DaSilva J; Bednarski E; Ramos V; Zong S; Johnson B; Raspe R; Schaefer-Babajew D; Shimeliovich I; Daga M; Yao KH; Schmidt F; Millard KG; Turroja M; Jankovic M; Oliveria TY; Gazumyan A; Caskey M; Hatziioannou T; Bieniasz PD; Nussenzweig MC
    bioRxiv; 2022 Feb; ():. PubMed ID: 35194607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine.
    Chen LL; Chua GT; Lu L; Chan BP; Wong JS; Chow CC; Yu TC; Leung AS; Lam SY; Wong TW; Tsang HW; Wong IC; Chan KH; Yuen KY; Ip P; Kwan MY; To KK
    Emerg Microbes Infect; 2022 Dec; 11(1):543-547. PubMed ID: 35084295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern.
    Valanparambil R; Carlisle J; Linderman S; Akthar A; Millett RL; Lai L; Chang A; McCook A; Switchenko J; Nasti T; Saini M; Andreas Wieland AW; Manning K; Ellis M; Moore K; Foster S; Floyd K; Davis-Gardner M; Viswanadh Edara V; Patel M; Steur C; Nooka A; Green F; Johns M; O Brein F; Shanmugasundaram U; Zarnitsyna V; Ahmed H; Nyhoff L; Mantus G; Garett M; Edupuganti S; Behra M; Antia R; Wrammert J; Suthar M; Dhodapkar M; Ramalingam S; Ahmed R
    medRxiv; 2022 Jan; ():. PubMed ID: 35018383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of Binding and Neutralizing Antibodies against SARS-CoV-2 Omicron Variant in Infection-Naïve and Convalescent BNT162b2 Recipients.
    Fu J; Shen X; Anderson M; Stec M; Petratos T; Cloherty G; Montefiori DC; Landay A; Moy JN
    Vaccines (Basel); 2022 Nov; 10(11):. PubMed ID: 36423000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test.
    Marot S; Bocar Fofana D; Flandre P; Malet I; Zafilaza K; Leducq V; Vivien D; Mrabet S; Poignon C; Calvez V; Morand-Joubert L; Marcelin AG; Gozlan J
    Life (Basel); 2022 Dec; 12(12):. PubMed ID: 36556429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Response to SARS-CoV-2 Vaccine and Following Breakthrough Omicron Infection in an Autoimmune Patient with Hashimoto's Thyroiditis, Pernicious Anemia, and Chronic Atrophic Autoimmune Gastritis: A Case Report.
    Cluff E; Bellusci L; Golding H; Khurana S
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex.
    Tang J; Grubbs G; Lee Y; Huang C; Ravichandran S; Forgacs D; Golding H; Ross TM; Khurana S
    EBioMedicine; 2021 Dec; 74():103748. PubMed ID: 34902788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines.
    Bowen JE; Sprouse KR; Walls AC; Mazzitelli IG; Logue JK; Franko NM; Ahmed K; Shariq A; Cameroni E; Gori A; Bandera A; Posavad CM; Dan JM; Zhang Z; Weiskopf D; Sette A; Crotty S; Iqbal NT; Corti D; Geffner J; Grifantini R; Chu HY; Veesler D
    bioRxiv; 2022 Mar; ():. PubMed ID: 35313570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins.
    Wang Z; Muecksch F; Cho A; Gaebler C; Hoffmann HH; Ramos V; Zong S; Cipolla M; Johnson B; Schmidt F; DaSilva J; Bednarski E; Tanfous TB; Raspe R; Yao K; Lee YE; Chen T; Turroja M; Milard KG; Dizon J; Kaczynska A; Gazumyan A; Oliveira TY; Rice CM; Caskey M; Bieniasz PD; Hatziioannou T; Barnes CO; Nussenzweig MC
    bioRxiv; 2022 Feb; ():. PubMed ID: 35132412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
    Cameroni E; Saliba C; Bowen JE; Rosen LE; Culap K; Pinto D; VanBlargan LA; De Marco A; Zepeda SK; Iulio JD; Zatta F; Kaiser H; Noack J; Farhat N; Czudnochowski N; Havenar-Daughton C; Sprouse KR; Dillen JR; Powell AE; Chen A; Maher C; Yin L; Sun D; Soriaga L; Bassi J; Silacci-Fregni C; Gustafsson C; Franko NM; Logue J; Iqbal NT; Mazzitelli I; Geffner J; Grifantini R; Chu H; Gori A; Riva A; Giannini O; Ceschi A; Ferrari P; Cippà P; Franzetti-Pellanda A; Garzoni C; Halfmann PJ; Kawaoka Y; Hebner C; Purcell LA; Piccoli L; Pizzuto MS; Walls AC; Diamond MS; Telenti A; Virgin HW; Lanzavecchia A; Veesler D; Snell G; Corti D
    bioRxiv; 2021 Dec; ():. PubMed ID: 34931194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization.
    Doria-Rose NA; Shen X; Schmidt SD; O'Dell S; McDanal C; Feng W; Tong J; Eaton A; Maglinao M; Tang H; Manning KE; Edara VV; Lai L; Ellis M; Moore K; Floyd K; Foster SL; Atmar RL; Lyke KE; Zhou T; Wang L; Zhang Y; Gaudinski MR; Black WP; Gordon I; Guech M; Ledgerwood JE; Misasi JN; Widge A; Roberts PC; Beigel J; Korber B; Pajon R; Mascola JR; Suthar MS; Montefiori DC
    medRxiv; 2021 Dec; ():. PubMed ID: 34931200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers.
    Nugent C; Abul Y; White E; Shehadeh F; Kaczynski M; Felix LO; Ganesan N; Oyebanji OA; Vishnepolskiy I; Didion EM; Paxitzis A; Sheehan ML; Mylonakis E; Wilson BM; Balazs AB; Chan PA; King CL; Pfeifer WM; Dickerson E; Canaday DH; Gravenstein S
    medRxiv; 2023 Jan; ():. PubMed ID: 36747765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of SARS-CoV-2 neutralizing antibody titers in breastmilk from convalescent and vaccinated mothers.
    Bäuerl C; Zulaica J; Rusu L; Moreno AR; Pérez-Cano FJ; Lerin C; Mena-Tudela D; Aguilar-Camprubí L; Parra-Llorca A; Martínez-Costa C; Geller R; Collado MC;
    iScience; 2023 Jun; 26(6):106802. PubMed ID: 37197591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles.
    Syed AM; Ciling A; Khalid MM; Sreekumar B; Chen PY; Kumar GR; Silva I; Milbes B; Kojima N; Hess V; Shacreaw M; Lopez L; Brobeck M; Turner F; Spraggon L; Taha TY; Tabata T; Chen IP; Ott M; Doudna JA
    medRxiv; 2022 Jan; ():. PubMed ID: 34981067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral Responses in the Omicron Era Following 3-Dose SARS-CoV-2 Vaccine Series in Kidney Transplant Recipients.
    McEvoy CM; Hu Q; Abe KT; Yau K; Oliver MJ; Levin A; Gingras AC; Hladunewich MA; Yuen DA
    Transplant Direct; 2023 Jan; 9(1):e1401. PubMed ID: 36518793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.